Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy

Atherosclerosis

Volumn 209, Issue 2, 2010, Pages 515-519

  Puzo, J ^a   Alfonso, P ^b,c   Irun, P ^b,c   Gervas, J ^b,c   Pocovi, M ^b,c,d   Giraldo, P ^b,c,e  

^a HOSPITAL SAN JORGE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^d UNIVERSITY OF ZARAGOZA   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Atherogenic; Coronary artery disease (CAD); Lipids; Lipoprotein; Miglustat; Substrate reduction therapy

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMIGLUCERASE; MIGLUSTAT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GAUCHER DISEASE; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

1-DEOXYNOJIRIMYCIN; ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; GAUCHER DISEASE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; RISK; TRIGLYCERIDES;

EID: 77950020023     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.10.015     Document Type: Article

References (30)

1. Beutler E., Grabowski G.A. Gaucher disease. The metabolic and molecular bases of inherited disease 2001, vol. 3:3635-3668. McGraw-Hill, New York.
2. Ginsberg H., Grabowski G.A., Gibson J.C., et al. Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease. Clin Genet 1984, 26:109-116.
3. Le N.A., Gibson J.C., Rubinstein A., Grabowski G.A., Ginsberg H.N. Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. Metabolism 1988, 37:240-245.
4. Pocovi M., Cenarro A., Civeira F., et al. Beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia. Lancet 1998, 351:1919-1923.
5. Weinreb N.J., Deegan P., Kacena K.A., et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008, 83:896-900.
6. Cox T., Lachmann R., Hollak C., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000, 355:1481-1485.
7. Heitner R., Elstein D., Aerts J., Weely S., Zimran A. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002, 28:127-133.
8. Weinreb N.J., Charrow J., Andersson H.C., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002, 113:112-119.
9. Pastores G.M., Barnett N.L., Kolodny E.H. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005, 27:1215-1227.
10. Aerts J.M., Hollak C.E., Boot R.G., Groener J.E., Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 2006, 29:449-456.
11. Giraldo P., Latre P., Alfonso P., et al. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease. Heamatologica 2006, 91:703-706.
12. Elstein D., Dweck A., Attias D., et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007, 110:2296-2301.
13. Hollak C.E., van Weely S., van Oers M.H., Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994, 93:1288-1292.
14. Cenarro A., Pocovi M., Giraldo P., Garcia-Otin A.L., Ordovas J.M. Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease. Lancet 1999, 353:642-643.
15. Alfonso P., Cenarro A., Pérez-Calvo J.I., et al. Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease. Med Clin (Barc) 2003, 120:641-646.
16. de Fost M., Langeveld M., Franssen R., et al. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 2009, 204:267-272.
17. Alfonso P., Aznarez S., Giralt M., Pocovi M., Giraldo P. Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet 2007, 52:391-396.
18. Zimram A., Kay A., Gelbart T., et al. Gaucher's disease clinical, laboratory, radiologic and genetic features of 53 patients. Medicine (Balt) 1992, 71:337-353.
19. Navab M., Yu R., Ghasavi N., Huang W., et al. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep 2007, 9:244-248.
20. Linsel-Nitschke P., Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005, 4:193-205.
21. Lewington S., Whitlock G., Clarke R., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-2183.
22. Cox T.M., Aerts J.M., Andria G., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003, 26:513-526.
23. Elstein D., Abrahamov A., Hadas-Halpern I., Zimran A. Withdrawal of enzyme replacement therapy in Gaucher disease. Br J Haematol 2000, 110:488-492.
24. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 104:1108-1113.
25. Jenner J.L., Ordovas J.M., Lamon-Fava S., et al. Effects of age, sex, and menopausal status on plasma lipoprotein (a) levels. The Framingham Offspring Study. Circulation 1993, 87:1135-1141.
26. Bassuk S.S., Rifai N., Ridker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004, 29:439-493.
27. NACBLMP Committee Members, Myers GL, Christenson RH, Cushman M et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009; 55:378-384.
28. Du Clos T.W. Function of C-reactive protein. Ann Med 2000, 32:274-278.
29. Brooks D.A., Kakavanos R., Hopwood J.J. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 2003, 9:450-453.
30. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.